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S U M M A R Y
We report the case of a 19-year-old male with possible cerebral mucormycosis following chemotherapy.
We detected a Lichtheimia DNA load of 2.0  104 copies/ml in cerebrospinal ﬂuid (CSF), although a CSF
culture showed no growth. After treatment with intravenous liposomal amphotericin B, the Lichtheimia
DNA load fell below the detection limit, and at the same time the patient’s headache and imaging
ﬁndings improved. The quantiﬁcation of Mucorales DNA in CSF may be useful for evaluating cerebral
mucormycosis.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-
nc-sa/3.0/).
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Cerebral mucormycosis is a life-threatening disease, requiring
early diagnosis and prompt intervention. However, mucormycosis
is difﬁcult to diagnose due to the lack of useful serum biomarkers.
Millon et al. developed a serodiagnostic tool utilizing quantitative
polymerase chain reaction (qPCR) to detect circulating Mucor/
Rhizopus, Lichtheimia, and Rhizomucor DNA in serum.1 Although
Millon et al. determined the relative amount of Mucorales DNA
from the number of PCR cycles,1 we modiﬁed their qPCR assay to
indicate the absolute amount for the monitoring of activity of
mucormycosis.2 Using the modiﬁed qPCR assay, we evaluated
changes in the Mucorales DNA load in cerebrospinal ﬂuid (CSF) as
well as serum in a patient with possible cerebral mucormycosis
treated with intravenous liposomal amphotericin B (L-AmB).
2. Case report
We report the case of a 19-year-old male with Philadelphia
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license (http://creativecommons.org/licenses/by-nc-sa/3.0/).a history of possible pulmonary and cerebral fungal infection,
negative for galactomannan antigen and by b-D-glucan tests,
during the neutropenia period following chemotherapy. Treatment
with high-dose L-AmB (5–10 mg/kg/day) improved the pulmonary
lesion, but the cerebellum nodule in the outer layer of the right
hemisphere remained. The patient was treated thereafter with
imatinib and 6-mercaptopurine for Ph+ALL and maintained
complete remission. For 1 year, the cerebellar nodule did not
change in size.
The patient was readmitted to hospital due to a 3-week
headache. Brain magnetic resonance imaging (MRI) revealed a new
nodule with peri-lesional edema in the outer layer dorsum of the
cerebellum right hemisphere (Figure 1A–C).
3. Materials and methods
We have previously reported a method for the absolute
quantiﬁcation of plasmid DNA containing a genomic DNA fragment
of Mucorales.2 Brieﬂy, DNA was extracted from 200 ml each of the
patient’s serum and cell-free CSF using the QIAamp DNA Blood
Mini Kit (Qiagen K.K., Tokyo, Japan), in accordance with the
manufacturer’s instructions. The sequences of primers and probes
to detect circulating DNA of Mucor/Rhizopus, Lichtheimia, orciety for Infectious Diseases. This is an open access article under the CC BY-NC-SA
Figure 1. Brain magnetic resonance imaging (MRI) before (A–C, left hand side) and after (D–F, right hand side) treatment with liposomal amphotericin B. Before treatment, the
outer layer dorsum of the cerebellum right hemisphere contained a ring-like nodular lesion (15 mm in diameter) on the enhanced T1-weighted image (A, coronal image; B,
axial image), with a large area of high-signal intensity on the T2-weighted image (C, axial image). A follow-up MRI after treatment demonstrates a decreased nodule size
(11 mm in diameter) on the enhanced T1-weighted image (D, coronal image; E, axial image) and a reduction of the high-signal intensity area on the T2-weighted image (F,
axial image). There was no change in the size of the nodule in the outer layer of the cerebellum right hemisphere before and after treatment.
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Agency website (http://www.epa.gov/nerlcwww/moldtech.htm#
primers). PCR reactions were run on an ABI 7900HT (Applied
Biosystems, Foster City, CA, USA). The thermal cycling conditions
were as follows: an initial denaturation step at 95 8C for 10 min,
followed by 50 cycles of 15 s at 95 8C and 1 min at 60 8C. Each assay
was designed against a six-point standard curve constructed using
Mucorales-speciﬁc sequence-containing plasmids at concentra-
tions ranging from 106 to 10 copies. The threshold cycle value for
each sample was plotted on the standard curve. We conﬁrmed
positivity of our qPCR assay for Lichtheimia corymbifera (IFM 5335),
which was obtained from the National BioResource Project(http://www.nbrp.jp/). The copy number of Mucorales DNA was
calculated and expressed as the copy number per milliliter of
sample. The detection limit is 1.0  103 copies/ml, which is
equivalent to 0.1 fg/ml, and is comparable to that of Millon et al.
(3.7–15 fg/10 ml).1
The study was approved by the Institutional Review Board of
Shinshu University School of Medicine.
4. Results
We detected circulating Lichtheimia DNA in the patient’s serum
using our qPCR assay (2.4  103 copies/ml). His CSF showed no
T. Shigemura et al. / International Journal of Infectious Diseases 29 (2014) 200–202202increased cell counts and no growth on microbiological culture;
however, the amount of Lichtheimia DNA was elevated to
2.0  104 copies/ml. Imatinib and 6-mercaptopurine treatment
was stopped and L-AmB (5 mg/kg/day) treatment was started.
Subsequently, his headache improved gradually. The serum DNA
loads on days 6 and 11 of L-AmB treatment were 1.2  103 and
1.3  103 copies/ml, respectively. After 16 days, the serum DNA
load was below the detection limit (<1.0  103 copies/ml).
Administration of L-AmB was continued for 17 days and then
discontinued due to the exacerbation of renal dysfunction. A
follow-up MRI demonstrated a reduction of the new nodule and
improvement of the edema in the circumference (Figure 1D–F).
The CSF contained no detectable Lichtheimia DNA (<1.0  103
copies/ml).
5. Discussion
Histopathological ﬁndings are usually required for a positive
mucormycosis diagnosis.3,4 However, in most cases, brain samples
cannot be obtained from suspected patients. In addition, Mucorales
are rarely detectable in CSF by conventional methods, even during
central nervous system infections.5 Of signiﬁcance, this qPCR
method was able to detect Lichtheimia DNA in CSF at disease onset
(2.0  104 copies/ml). Furthermore, the DNA load in CSF decreased
to below the detection limit, and this occurred together with an
improvement in the clinical manifestations and MRI ﬁndings after
treatment. By contrast, the Lichtheimia DNA loads in the serialserum samples from onset were near the detection limit (1.2–
2.4  103 copies/ml). Although our observation is based on a single
case, it is suggested that the quantiﬁcation of Mucorales DNA in CSF
is useful for the diagnosis and evaluation of the therapeutic effect
in cerebral mucormycosis.
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